Early Progression in Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Treated with Pembrolizumab in First-Line Setting: A Prognostic Scoring System Based on Clinical Features

SIMPLE SUMMARY: Immune checkpoint inhibitors demonstrated a survival advantage in the first-line setting in patients with non-oncogene addicted non-small cell lung cancer (NSCLC) and PD-L1 expression ≥50%. However, some patients have detrimental effects from this treatment, but no consistent data ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Passaro, Antonio, Novello, Silvia, Giannarelli, Diana, Bria, Emilio, Galetta, Domenico, Gelibter, Alain, Reale, Maria Lucia, Carnio, Simona, Vita, Emanuele, Stefani, Alessio, Pizzutilo, Pamela, Stati, Valeria, Attili, Ilaria, de Marinis, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230881/
https://www.ncbi.nlm.nih.gov/pubmed/34208253
http://dx.doi.org/10.3390/cancers13122935

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230881/
https://www.ncbi.nlm.nih.gov/pubmed/34208253
http://dx.doi.org/10.3390/cancers13122935

Ejemplares similares